GlaxoSmithKline (GSK) and Theravance have received marketing authorization from the European Commission (EC) for their jointly-developed asthma and chronic obstructive pulmonary disease (COPD) drug 'Relvar Ellipta'. Relvar, which is a ...
Tags: GSK, Relvar Ellipta
UK-based GlaxoSmithKline (GSK) and US-based Theravance have announced the availability of BREO ELLIPTA, a once-daily prescription medicine for chronic obstructive pulmonary disease (COPD), in the US pharmacies. BREO ELLIPTA is a ...
The Cyber Security Challenge UK (CSC UK), a series of national events designed to encourage talented professionals to join the UK IT security industry, is a government- and industry-backed initiative that has enabled 40 participants to ...
Tags: Computer Products, software
British drug maker GlaxoSmithKline (GSK) has received positive opinion from the European Medicines Agency (EMA's) Committee for Medicinal Products for Human Use (CHMP) for additional indication for Synflorix, a pediatric pneumococcal ...
Tags: drug, Pneumonia Indication
UK-based pharmaceutical company GlaxoSmithKline (GSK) has reached an agreement with Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP), the Brazilian funding agency for scientific research, to establish a new center of excellence ...
Tags: Sustainable Chemistry, Medicine
GlaxoSmithKline (GSK) has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for the once daily inhaled corticosteroid (ICS) treatment, fluticasone furoate (FF), administered using the ELLIPTA dry powder ...
Tags: Asthma Treatment, Medicine
Cannabis Biotech, a subsidiary of Puget Technologies, is introducing product research for a transmucosal delivery system to deliver medical marijuana through the mucous membrane of the nasal cavity. Cannabis Biotech's new project is ...
Tags: Cannabis Biotech
GlaxoSmithKline (GSK) and Danish biotechnology firm Genmab have filed a supplemental Biologics License Application (sBLA) to the US Food and Drug Administration (FDA) for the use of its leukaemia drug Arzerra (ofatumumab) in combination ...
Tags: GlaxoSmithKline, CLL Patients
Danish biotechnology firm Genmab has unveiled positive results from a Phase II study of its sclerosis drug candidate ofatumumab in relapsing-remitting multiple sclerosis (RRMS). In a randomized study of 232 patients with RRMS, treatment ...
Tags: Genmab, Sclerosis Drug
GlaxoSmithKline’s sale of Lucozade and Ribena for £1.35bn earlier this month was the latest in a long line of iconic British brand sales topped by Cadbury. GlaxoSmithKline's sale of its drinks brands was the latest in a long ...
Tags: Timeline Tracks, Food Brands
GlaxoSmithKline and biopharmaceutical company Theravance have announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended marketing approval for fluticasone furoate/vilanterol ...
The US Food and Drug Administration (FDA) has approved breakthrough therapy designation for Danish biotechnology company Genmab and British pharmaceutical company GlaxoSmithKline’s (GSK) Arzerra (ofatumumab) in combination with ...
Tags: therapy designation, Medicine
The Pulmonary-Allergy Drugs Advisory Committee (PADAC) of the US Food and Drug Administration (FDA) has recommended the approval of GlaxoSmithKline (GSK) and Theravance's umeclidinium/vilanterol as a treatment for chronic obstructive ...
Tags: Health, Medicine, Investigational Copd Drug
One of the world's top-selling drugs—GlaxoSmithKline PLC's $8-billion-a-year asthma treatment Advair—became more vulnerable to generic competition after the U.S. Food and Drug Administration issued guidance on the regulatory ...
GlaxoSmithKline is to sell its drinks brands Lucozade and Ribena to Suntory Beverage & Food Ltd (SBF), the Japanese consumer goods company, for GBP 1.35 billion (AUD 2.4b) in cash. It is expected that the transaction will be completed by ...
Tags: Beverage, Food, Agriculture